Additional information
| Active substance | Pyridostigmine Bromide |
|---|---|
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | Monitoring of cholinesterase levels may be conducted to assess efficacy and dosage requirements |
| Also known as | Mestinon, Regonol |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Can cause fluctuations, typically lowering blood pressure due to vasodilation |
| Trade name | Mestinon, Regonol |
| Storage conditions | Store at room temperature, away from moisture and heat |
| Chemical name | 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate |
| Formula | C9H13BrN2O2 |
| Substance class | Acetylcholinesterase inhibitor |
| Main action | Inhibits the breakdown of acetylcholine, thereby increasing its concentration at neuromuscular junctions |
| Half-life | Approximately 1.78 to 2.25 hours |
| Dosage (medical) | Typical starting dose for adults in the treatment of myasthenia gravis is 60 mg taken orally every 4 hours but can vary based on individual patient needs and conditions |
| Dosage (sports) | Not applicable as it is not legally used to enhance athletic performance |
| Effects | Improved muscle strength in patients with myasthenia gravis |
| Side effects | Nausea, vomiting, diarrhea, abdominal cramps, increased salivation and sweating, muscle cramps, and twitching |
| Use in sports | Not used or recommended |
| Manufacturer | Meda Pharma |
Reviews
There are no reviews yet.